

# Jeremie Calais

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6625346/publications.pdf>

Version: 2024-02-01

118  
papers

4,930  
citations

101543

36  
h-index

102487

66  
g-index

121  
all docs

121  
docs citations

121  
times ranked

3621  
citing authors

#	ARTICLE	IF	CITATIONS
1	Non-oncologic incidental uptake on FAPI PET/CT imaging. British Journal of Radiology, 2023, 96, .	2.2	25
2	Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study. European Urology Oncology, 2022, 5, 544-552.	5.4	16
3	Identifying the Best Candidates for Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as the Primary Staging Approach Among Men with High-risk Prostate Cancer and Negative Conventional Imaging. European Urology Oncology, 2022, 5, 100-103.	5.4	18
4	Tumor Sink Effect in <sup>68</sup> Ga-PSMA-11 PET: Myth or Reality?. Journal of Nuclear Medicine, 2022, 63, 226-232.	5.0	42
5	<sup>18</sup> F-FDG PET/CT Imaging Biomarkers for Early and Late Evaluation of Response to First-Line Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma. Journal of Nuclear Medicine, 2022, 63, 199-204.	5.0	3
6	A Comprehensive Assessment of <sup>68</sup> Ga-PSMA-11 PET in Biochemically Recurrent Prostate Cancer: Results from a Prospective Multicenter Study on 2,005 Patients. Journal of Nuclear Medicine, 2022, 63, 567-572.	5.0	20
7	Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging. Journal of Nuclear Medicine, 2022, 63, 59-68.	5.0	61
8	PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter Study. Journal of Nuclear Medicine, 2022, 63, 76-80.	5.0	20
9	Refining the definition of biochemical failure in the era of stereotactic body radiation therapy for prostate cancer: The Phoenix definition and beyond. Radiotherapy and Oncology, 2022, 166, 1-7.	0.6	9
10	Imaging Prostate Cancer: Clinical Utility of Prostate-Specific Membrane Antigen. Journal of Urology, 2022, 207, 769-778.	0.4	12
11	Initial evaluation of [ <sup>18</sup> F]-FACBC for PET imaging of multiple myeloma. EJNMMI Research, 2022, 12, 4.	2.5	4
12	PSMA PET in Prostate Cancer—A Biomarker or a Surrogate End Point?—Reply. JAMA Oncology, 2022, , .	7.1	0
13	Health Care and Nuclear Medicine in France. Journal of Nuclear Medicine, 2022, 63, 327-330.	5.0	0
14	Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study. Journal of Nuclear Medicine, 2022, , jnumed.121.263072.	5.0	28
15	Predictors and Real-World Use of Prostate-Specific Radioligand Therapy: PSMA—And Beyond. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, , 366-382.	3.8	12
16	How Many Theranostics Centers Will We Need in the United States?. Journal of Nuclear Medicine, 2022, 63, 805-806.	5.0	6
17	More Unacceptable Denials: Now It's PSMA-Targeted PET/CT Imaging. Journal of Nuclear Medicine, 2022, 63, 969-970.	5.0	3
18	[ <sup>177</sup> Lu]Lu-PSMA-617 in PSMA-positive metastatic castration-resistant prostate cancer: Prior and concomitant treatment subgroup analyses of the VISION trial.. Journal of Clinical Oncology, 2022, 40, 5001-5001.	1.6	15

#	ARTICLE	IF	CITATIONS
19	Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 4271-4281.	6.4	38
20	Mechanisms of Resistance to Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2021, 62, jnumed.120.256263.	5.0	22
21	Radiation Dosimetry of <sup>99m</sup> Tc-PSMA I&S: A Single-Center Prospective Study. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1075-1081.	5.0	17
22	A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). <i>European Urology</i> , 2021, 80, 280-292.	1.9	140
23	<sup>68</sup> Ga-FAPi-46 diffuse bilateral breast uptake in a patient with cervical cancer after hormonal stimulation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 924-926.	6.4	19
24	Will FAPI PET/CT Replace FDG PET/CT in the Next Decade? Point-Of-View: An Important Diagnostic, Phenotypic, and Biomarker Role. <i>American Journal of Roentgenology</i> , 2021, 216, 305-306.	2.2	36
25	False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 501-508.	6.4	30
26	The Impact of Monosodium Glutamate on <sup>68</sup> Ga-PSMA-11 Biodistribution in Men with Prostate Cancer: A Prospective Randomized, Controlled Imaging Study. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1244-1251.	5.0	10
27	Oliver Sartor Talks with Thomas A. Hope, Jeremie Calais, and Wolfgang P. Fendler About FDA Approval of PSMA. <i>Journal of Nuclear Medicine</i> , 2021, 62, 146-148.	5.0	15
28	PSMA-targeted radiopharmaceutical therapy in patients with metastatic castration-resistant prostate cancer. <i>Lancet, The</i> , 2021, 397, 768-769.	13.7	5
29	Accuracy of <sup>18</sup> F-Fluorocholine PET for the Detection of Parathyroid Adenomas: Prospective Single-Center Study. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1511-1516.	5.0	15
30	We Can Make a Difference: Investigator-driven Prostate-specific Membrane Antigen Radiotheranostics for Prostate Cancer. <i>European Urology Focus</i> , 2021, 7, 227-228.	3.1	0
31	Update from PSMA-SRT Trial NCT03582774: A Randomized Phase 3 Imaging Trial of Prostate-specific Membrane Antigen Positron Emission Tomography for Salvage Radiation Therapy for Prostate Cancer Recurrence Powered for Clinical Outcome. <i>European Urology Focus</i> , 2021, 7, 238-240.	3.1	31
32	Abstract PO-077: Study evaluating metastatic castrate resistant prostate cancer (mCRPC) treatment using <sup>177</sup> Lu-PNT2002 PSMA therapy after second-line hormonal treatment (SPLASH) - Trial in progress. <i>Clinical Cancer Research</i> , 2021, 27, PO-077-PO-077.	7.0	3
33	<sup>68</sup> Ga-FAPi-46 and <sup>18</sup> F-FDG PET/CT in a patient with immune-related thyroiditis induced by immune checkpoint inhibitors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3736-3737.	6.4	15
34	Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol. <i>BMC Cancer</i> , 2021, 21, 512.	2.6	14
35	Prostate-specific Membrane Antigen PET in Prostate Cancer. <i>Radiology</i> , 2021, 299, 248-260.	7.3	38
36	Prospective phase 2 trial of PSMA-targeted molecular Radiotherapy with <sup>177</sup> Lu-PSMA-617 for metastatic castration-resistant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1440-1446.	5.0	37

#	ARTICLE	IF	CITATIONS
37	<sup>177</sup> Lu-PSMA617 and the VISION Trial: One of the Greatest Success Stories in the History of Nuclear Medicine. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1025-1026.	5.0	8
38	Use and Impact of Positron Emission Tomography/Computed Tomography Prior to Salvage Radiation Therapy in Men with Biochemical Recurrence After Radical Prostatectomy: A Scoping Review. <i>European Urology Oncology</i> , 2021, 4, 339-355.	5.4	20
39	Head-to-head intra-individual comparison of biodistribution and tumor uptake of <sup>68</sup> Ga-FAPI and <sup>18</sup> F-FDG PET/CT in cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4377-4385.	6.4	114
40	<sup>177</sup> Lu-PSMA617 and the VISION Trial: One of the Greatest Success Stories in the History of Nuclear Medicine. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1025-1026.	5.0	0
41	Perspectives on Cutting-Edge Clinical Trials. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1027-1030.	5.0	0
42	Safety of PSMA-Targeted Molecular Radioligand Therapy with <sup>177</sup> Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312). <i>Journal of Nuclear Medicine</i> , 2021, 62, 1447-1456.	5.0	14
43	Salvage therapy for prostate cancer after radical prostatectomy. <i>Nature Reviews Urology</i> , 2021, 18, 643-668.	3.8	26
44	Nomograms to predict outcomes after <sup>177</sup> Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. <i>Lancet Oncology</i> , The, 2021, 22, 1115-1125.	10.7	120
45	Diagnostic Accuracy of <sup>68</sup> Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection. <i>JAMA Oncology</i> , 2021, 7, 1635.	7.1	138
46	High <sup>68</sup> Ga-FAPI-46 uptake in a pulmonary necrotizing granuloma in a patient with subcutaneous lipoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, , 1.	6.4	3
47	Incidental Detection of Elastofibroma Dorsi With <sup>68</sup> Ga-FAPI-46 and <sup>18</sup> F-FDG PET/CT in a Patient With Esophageal Cancer. <i>Clinical Nuclear Medicine</i> , 2021, 46, e86-e87.	1.3	13
48	PSMA Expression Assessed by PET Imaging Is a Required Biomarker for Selecting Patients for Any PSMA-Targeted Therapy. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1489-1491.	5.0	11
49	Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer. <i>JAMA Network Open</i> , 2021, 4, e2138550.	5.9	18
50	Total-Body <sup>68</sup> Ga-PSMA-11 PET/CT for Bone Metastasis Detection in Prostate Cancer Patients: Potential Impact on Bone Scan Guidelines. <i>Journal of Nuclear Medicine</i> , 2020, 61, 405-411.	5.0	36
51	Can the Injected Dose Be Reduced in <sup>68</sup> Ga-PSMA-11 PET/CT While Maintaining High Image Quality for Lesion Detection?. <i>Journal of Nuclear Medicine</i> , 2020, 61, 189-193.	5.0	19
52	Radiation Dosimetry and Biodistribution of <sup>68</sup> Ga-FAPI-46 PET Imaging in Cancer Patients. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1171-1177.	5.0	136
53	Mapping Prostate Cancer Lesions Before and After Unsuccessful Salvage Lymph Node Dissection Using Repeat PSMA PET. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1037-1042.	5.0	19
54	Non-invasive imaging techniques to assess myocardial perfusion. <i>Expert Review of Medical Devices</i> , 2020, 17, 1133-1144.	2.8	8

#	ARTICLE	IF	CITATIONS
55	PSMA Expression in the Neovasculature Associated With Rectal Adenocarcinoma. <i>Clinical Nuclear Medicine</i> , 2020, 45, e309-e310.	1.3	4
56	Impact of <sup>68</sup> Ga-PSMA-11 PET on the management of biochemically recurrent prostate cancer in a prospective single-arm clinical trial. <i>European Urology Open Science</i> , 2020, 19, e1215-e1216.	0.4	2
57	The Impact of <sup>18</sup> F-DCFPyL PET-CT Imaging on Initial Staging, Radiation, and Systemic Therapy Treatment Recommendations for Veterans With Aggressive Prostate Cancer. <i>Advances in Radiation Oncology</i> , 2020, 5, 1364-1369.	1.2	5
58	Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting. <i>Prostate</i> , 2020, 80, 1273-1296.	2.3	16
59	Impact of <sup>68</sup> Ga-PSMA-11 PET on the Management of Recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1793-1799.	5.0	74
60	PSMA-targeted Radiotracers versus <sup>18</sup> F Fluciclovine for the Detection of Prostate Cancer Biochemical Recurrence after Definitive Therapy: A Systematic Review and Meta-Analysis. <i>Radiology</i> , 2020, 296, 44-55.	7.3	49
61	Efficacy and Safety of <sup>177</sup> Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study. <i>European Urology</i> , 2020, 78, 148-154.	1.9	39
62	Correlation Between FDG Hotspots on Pre-radiotherapy PET/CT and Areas of HNSCC Local Relapse: Impact of Treatment Position and Images Registration Method. <i>Frontiers in Medicine</i> , 2020, 7, 218.	2.6	3
63	Correlation between fluorodeoxyglucose hotspots on preradiotherapy PET/CT and areas of cancer local relapse: Systematic review of literature. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2020, 24, 444-452.	1.4	3
64	FAP: The Next Billion Dollar Nuclear Theranostics Target?. <i>Journal of Nuclear Medicine</i> , 2020, 61, 163-165.	5.0	64
65	Impact of <sup>68</sup> Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1153-1160.	5.0	94
66	Impact of <sup>68</sup> Ga-PSMA-11 PET on the Management of biochemically recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial. <i>Nuklearmedizin - NuclearMedicine</i> , 2020, 59, .	0.7	2
67	[ <sup>18</sup> F]FDG PET/CT for evaluating early response to neoadjuvant chemotherapy in pediatric patients with sarcoma: a prospective single-center trial. <i>EJNMMI Research</i> , 2020, 10, 122.	2.5	8
68	Overall survival after <sup>177</sup> Lu-PSMA-617 molecular radiotherapy in patients with metastatic castrate-resistant prostate cancer: Post-hoc analysis of a prospective phase II trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5549-5549.	1.6	4
69	Nuclear Medicine, Molecular Imaging, and Theranostics: The Future Is Bright. <i>Journal of Nuclear Medicine Technology</i> , 2020, 48, 82S-83S.	0.8	0
70	Diagnostic Impact of <sup>18</sup> F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and White Blood Cell SPECT/Computed Tomography in Patients With Suspected Cardiac Implantable Electronic Device Chronic Infection. <i>Circulation: Cardiovascular Imaging</i> , 2019, 12, e007188.	2.6	52
71	<sup>18</sup> F-fluciclovine PET-CT and <sup>68</sup> Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. <i>Lancet Oncology</i> , The, 2019, 20, 1286-1294.	10.7	338
72	What is the best PET target for early biochemical recurrence of prostate cancer?â€“Authorsâ€™ reply. <i>Lancet Oncology</i> , The, 2019, 20, e609-e610.	10.7	4

#	ARTICLE	IF	CITATIONS
73	The Future of Nuclear Medicine as an Independent Specialty. <i>Journal of Nuclear Medicine</i> , 2019, 60, 3S-12S.	5.0	47
74	Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 7448-7454.	7.0	190
75	<sup>111</sup> In-Pentetreotide Scintigraphy Versus <sup>68</sup> Ga-DOTATATE PET: Impact on Krenning Scores and Effect of Tumor Burden. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1266-1269.	5.0	66
76	Assessment of <sup>68</sup> Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer. <i>JAMA Oncology</i> , 2019, 5, 856.	7.1	493
77	Prostate Cancer Pulmonary Metastasis Presenting as a Ground-Glass Pulmonary Nodule on <sup>68</sup> Ga-PSMA-11 PET/CT. <i>Clinical Nuclear Medicine</i> , 2019, 44, e353-e356.	1.3	5
78	Randomized prospective phase III trial of <sup>68</sup> Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]. <i>BMC Cancer</i> , 2019, 19, 18.	2.6	86
79	Solitary Mucinous Prostate Adenocarcinoma Lung Metastasis Detected by <sup>68</sup> Ga-PSMA-11 PET/CT. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e53-e55.	1.9	8
80	Metaanalysis of <sup>68</sup> Ga-PSMA-11 PET Accuracy for the Detection of Prostate Cancer Validated by Histopathology. <i>Journal of Nuclear Medicine</i> , 2019, 60, 786-793.	5.0	169
81	Imaging of Prostate Specific Membrane Antigen Targeted Radiotracers for the Detection of Prostate Cancer Biochemical Recurrence after Definitive Therapy: A Systematic Review and Meta-Analysis. <i>Journal of Urology</i> , 2019, 202, 231-240.	0.4	46
82	<sup>68</sup> Ga-PSMA-11 Positron Emission Tomography Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective Study. <i>Journal of Urology</i> , 2019, 202, 1174-1181.	0.4	33
83	Evaluation of SUV normalized by lean body mass (SUL) in <sup>68</sup> Ga-PSMA11 PET/CT: a bi-centric analysis. <i>EJNMMI Research</i> , 2019, 9, 103.	2.5	11
84	RESIST-PC phase 2 trial: <sup>177</sup> Lu-PSMA-617 radionuclide therapy for metastatic castrate-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5028-5028.	1.6	11
85	Prospective head-to-head comparison of <sup>18</sup> F-fluciclovine and <sup>68</sup> Ga-PSMA-11 PET/CT for localization of prostate cancer biochemical recurrence after primary prostatectomy.. <i>Journal of Clinical Oncology</i> , 2019, 37, 15-15.	1.6	8
86	Randomized phase III trial of <sup>68</sup> Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT].. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS136-TPS136.	1.6	3
87	Prospective head-to-head comparative phase 3 study between <sup>18</sup> F-fluciclovine and <sup>68</sup> Ga-PSMA-11 PET/CT in patients with early biochemical recurrence of prostate cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5014-5014.	1.6	0
88	Randomized prospective phase 3 trial of <sup>68</sup> Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT].. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS5101-TPS5101.	1.6	1
89	Reply by Authors. <i>Journal of Urology</i> , 2019, 202, 1181-1181.	0.4	0
90	Of Sheep and Wolves: Curtailing Coverage for Essential Imaging Tests Based on Flawed Use and Cost Arguments. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1657-1658.	5.0	1



#	ARTICLE	IF	CITATIONS
91	Delivering Radionuclide Therapies Requires Extensive Training and Competence: Send a Firm Message to the NRC and Your Representatives. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1-2.	5.0	57
92	Reply: Comparison of <sup>68</sup> Ga-PSMA-11 and <sup>18</sup> F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence: Prospective Trial Is on Its Way. <i>Journal of Nuclear Medicine</i> , 2018, 59, 861-861.	5.0	7
93	Potential Impact of <sup>68</sup> Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1714-1721.	5.0	81
94	Comparison of <sup>68</sup> Ga-PSMA-11 and <sup>18</sup> F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence. <i>Journal of Nuclear Medicine</i> , 2018, 59, 789-794.	5.0	68
95	The Utility of PET/CT in the Planning of External Radiation Therapy for Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 557-567.	5.0	41
96	Detection Threshold and Reproducibility of <sup>68</sup> Ga-PSMA11 PET/CT in a Mouse Model of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1392-1397.	5.0	21
97	A Cardiac Myxoma With Intense Metabolic Activity. <i>Canadian Journal of Cardiology</i> , 2018, 34, 92.e11-92.e12.	1.7	4
98	Impact of <sup>68</sup> Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence. <i>Journal of Nuclear Medicine</i> , 2018, 59, 434-441.	5.0	113
99	Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed mITNM Classification for the Interpretation of PSMA-Ligand PET/CT. <i>Journal of Nuclear Medicine</i> , 2018, 59, 469-478.	5.0	372
100	<sup>68</sup> Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning. <i>Journal of Nuclear Medicine</i> , 2018, 59, 230-237.	5.0	226
101	Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer. <i>EJNMMI Research</i> , 2018, 8, 96.	2.5	58
102	<sup>68</sup> Ga-PSMA PET/CT Mapping of Prostate Cancer at Initial Staging: Potential Impact on Definitive Radiation Therapy Planning. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, S162.	0.8	0
103	The influence of PSA flare in mCRPC patients treated with alpha-emitting radiopharmaceuticals. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2253-2255.	6.4	0
104	Accuracy of <sup>68</sup> Ga-PSMA11 PET/CT on recurrent prostate cancer: Preliminary results from a phase 2/3 prospective trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5001-5001.	1.6	6
105	Mycotic aneurysm in a pulmonary artery detected with <sup>18</sup> F-fluorodeoxyglucose positron emission tomography/computed tomography imaging. <i>European Heart Journal</i> , 2017, 38, ehw571.	2.2	7
106	<sup>68</sup> Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1617-1623.	5.0	111
107	Most of the Intended Management Changes After <sup>68</sup> Ga-DOTATATE PET/CT Are Implemented. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1793-1796.	5.0	24
108	Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2017, 39, 1155-1165.	2.0	16

#	ARTICLE	IF	CITATIONS
109	Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy. <i>Journal of Nuclear Medicine</i> , 2017, 58, 67S-76S.	5.0	163
110	Reply to "18F-Choline PET-CT in the Management of Lung Cancer and Mucinous Tumors". <i>Journal of Thoracic Oncology</i> , 2015, 10, e49-e50.	1.1	3
111	Areas of High <sup>18</sup> F-FDG Uptake on Preradiotherapy PET/CT Identify Preferential Sites of Local Relapse After Chemoradiotherapy for Non-Small Cell Lung Cancer. <i>Journal of Nuclear Medicine</i> , 2015, 56, 196-203.	5.0	59
112	Tc-99m-HMPAO-Labeled Leukocyte SPECT/CT in Pediatrics: Detecting <i>Candida albicans</i> Tricuspid Endocarditis. <i>Nuclear Medicine and Molecular Imaging</i> , 2015, 49, 333-334.	1.0	1
113	High FDG uptake areas on pre-radiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for locally advanced oesophageal cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 858-867.	6.4	38
114	Resection of a Solitary Pulmonary Metastasis from Prostatic Adenocarcinoma Misdiagnosed as a Bronchocele: Usefulness of 18F-Choline and 18F-FDG PET/CT. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1826-1829.	1.1	8
115	Hodgkin's Disease Staging by FDG PET/CT in a Pregnant Woman. <i>Nuclear Medicine and Molecular Imaging</i> , 2014, 48, 244-246.	1.0	12
116	18F-FDG PET/CT scan in malignant priapism with diffuse pulmonary adenocarcinoma metastatic invasion of both corpus spongiosum and cavernosum. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 588-589.	6.4	5
117	Douleurs jambières bilatérales sans orientation étiologique évidente. <i>Feuillets De Radiologie</i> , 2012, 52, 342-346.	0.0	0
118	Development and Validation of Nomograms to Predict Outcome Following LuPSMA Radionuclide Treatment for Metastatic Castration-Resistant Prostate Cancer: A Multicenter International Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0